Wide Ranks

KURA

Kura Oncology, Inc.

11.17

Top Statistics
Market Cap 868 M Forward PE -5.84 Revenue Growth 0.00 %
Current Ratio 11.47 Trailing PE 0.0000 Earnings Growth 0.00 %
Profit Margins 0.00 % Peg Ratio Dividend Yield 0.00 %
Enterprice / EBITA -1.99 Enterprise / Revenue Price To Sales Trailing12 Months
Profitability
Profit Margins 0.00 % Operating Margins
Balance Sheet
Total Cash 455 M Total Cash Per Share 5.86 Total Debt 16 M
Total Debt To Equity 3.92 Current Ratio 11.47 Book Value Per Share 5.45
All Measures
Short Ratio 1467.00 % Message Board Id finmb_282774456 Shares Short Prior Month 9 M
Return On Equity -0.4628 City San Diego Uuid d959d119-9140-35ab-8205-a916e1fac9db
Previous Close 10.75 First Trade Date Epoch Utc 1 B Book Value 5.45
Beta 0.8570 Total Debt 16 M Volume 4 M
Price To Book 2.05 Fifty Two Week Low 9.18 Total Cash Per Share 5.86
Shares Short Previous Month Date 1 B Target Median Price 29.50 Audit Risk 2
Max Age 86400 Recommendation Mean 1.44 Sand P52 Week Change 0.3133
Target Mean Price 28.57 Net Income To Common -197552000 Short Percent Of Float 0.1433
Implied Shares Outstanding 77 M Trailing Peg Ratio None Last Fiscal Year End 1 B
Average Daily Volume10 Day 4 M Average Volume10days 4 M Total Cash 455 M
Next Fiscal Year End 1 B Held Percent Insiders 0.0105 Trailing PE 0.0000
Date Short Interest 1 B Most Recent Quarter 1 B Share Holder Rights Risk 8
Regular Market Previous Close 10.75 Target Low Price 11.00 Gmt Off Set Milliseconds -18000000
Fifty Day Average 17.31 Open 10.89 Free Cashflow -93215000
State CA Dividend Yield 0.00 % Return On Assets -0.2854
Time Zone Short Name EST Board Risk 7 Trailing Eps -2.35
Day Low 10.71 Address1 12730 High Bluff Drive Shares Outstanding 77 M
Compensation Risk 6 Price Hint 2 Target High Price 37.00
Website https://kuraoncology.com 52 Week Change 0.1551 Average Volume 1 M
Forward Eps -2.67 Recommendation Key strong_buy Compensation As Of Epoch Date 1 B
Quick Ratio 1139.40 % Is_sp_500 False Regular Market Day High 11.37
Profit Margins 0.00 % Debt To Equity 3.92 Fifty Two Week High 24.17
Day High 11.37 Shares Short 11 M Regular Market Open 10.89
Industry Key biotechnology Earnings Growth 0.00 % Revenue Growth 0.00 %
Shares Percent Shares Out 0.1419 Operating Cashflow -169122000 Currency USD
Time Zone Full Name America/New_York Market Cap 868 M Is_nasdaq_100 False
Zip 92130 Quote Type EQUITY Industry Biotechnology
Long Name Kura Oncology, Inc. Overall Risk 6 Regular Market Day Low 10.71
Held Percent Institutions 1.08 Current Price 11.17 Address2 Suite 400
Enterprise To Ebitda -1.99 Financial Currency USD Current Ratio 11.47
Industry Disp Biotechnology Number Of Analyst Opinions 14 Country United States
Float Shares 50 M Two Hundred Day Average 19.80 Governance Epoch Date 1 B
Enterprise Value 429 M Forward PE -5.84 Regular Market Volume 4 M
Ebitda -216644000 Exchange NMS
Go to Yahoo Finance Go to Seeking Alpha 
Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer.

The company's pipeline consists of small molecule product candidates that target cancer.

Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.

It has a clinical collaboration with Novartis Pharma AG to evaluate the combination of tipifarnib and alpelisib in patients with head and neck squamous cell carcinoma whose tumors have HRAS overexpression and/or PIK3CA mutation and/or amplification.

The company was founded in 2014 and is headquartered in San Diego, California.